5月19日至20日，深交所2025全球投资者大会在深圳举行。在《境外市场优秀发展实践与跨境合作机 遇》的圆桌讨论上，沙特奥贝坎投资集团风险投资首席执行官Imtiaz Mahtab发表讲话。 Imtiaz Mahtab表示，沙特2030愿景与中国"一带一路"倡议的深度协同。作为管理400亿美元资产的四大 沙特家族办公室代表，其透露近三年已累计采购500亿美元中国产品与服务，成为全球最大中国商品服 务采购方之一。 马赫塔布指出，沙特当前经济转型态势堪比"2000年的中国"，正以超常规速度推进数万亿美元规模基建 项目，涵盖公路、铁路、体育馆及智慧城市等多元领域。中国企业在沙特工业化进程中已发挥关键作 用，去年已有三家上市中企在当地建立生产基地，通过本土化合作显著提升企业价值。 专题：专题｜深交所2025全球投资者大会：投资中国就是投资未来 "基础设施建设仍是首要引擎，但合作焦点正在向科技领域延伸。"Imtiaz Mahtab强调，继传统基建合作 后，中沙双方将在新能源汽车、电池技术、电子制造等深圳优势产业展开深度协作。沙特主权基金将发 挥战略投资者作用，既在项目层面提供资金支持，更通过股权投资助力企业价值提升。 值 ...

Financial Data and Key Metrics Changes - General and administrative expenses decreased by 14% to approximately $2.3 million compared to Q1 2024, primarily due to reduced stock-based compensation and headcount [13] - Research and development expenses decreased by 31% to approximately $2.3 million compared to Q1 2024 [13] - Comprehensive loss for the quarter was approximately $4.4 million, with cash and cash equivalents at approximately $10.3 million and a working capital deficit of approximately $9.4 million [13][14] Business Line Data and Key Metrics Changes - The company plans to commercialize three additional solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026, targeting a $4.5 billion compounded hormone therapy market [5][19] - The company expects to start recording revenue in the fourth quarter of 2025 [6][67] Market Data and Key Metrics Changes - The women's health sector is described as underfunded and fragmented, presenting significant opportunities for returns [7][67] - The company is leveraging a dual path strategy to commercialize products via 503B compounding while seeking FDA approval [7][24] Company Strategy and Development Direction - The company is focused solely on women's health, aiming to provide evidence-based solutions through various channels, including telehealth and online platforms [8][21] - The strategy includes forming partnerships with telehealth providers and online retailers to enhance product accessibility [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's unique position to deliver value amidst distractions in the healthcare and biotech sectors [6] - The company aims to meet the increasing demand for evidence-based treatments and is committed to rapid commercialization [16][17] Other Important Information - The company is actively evaluating the dual path approach for other proprietary formulations to expedite market access [24] - The company received a grant from the Gates Foundation to identify evidence-based formulations for vaginal probiotics [10][19] Q&A Session Summary Question: Will there be unique partnerships for each product or multiple partnerships for an individual product? - Management clarified that they intend to have multiple partnerships for individual products to ensure wide access [33] Question: Is there sufficient manufacturing capacity for Sildenafil Cream by year-end? - Management confirmed the need to support their 503B collaborator to ensure manufacturing readiness [35] Question: What additional information has the FDA requested for Sildenafil? - Management indicated that the FDA requested information regarding patient-reported outcomes and psychometrics, which is critical for the Phase III study [44][46] Question: Will the grant cover costs to add additional sites for Ovaprene? - Management confirmed that the grant is designed to cover costs associated with adding subjects to the study [56] Question: Should R&D expenses be expected to continue at the current lower level? - Management stated that the current trend reflects the absence of ongoing studies, and expenses may remain lower until new studies commence [58]

5月7日，王老吉大健康公司广州生物岛总部正式揭牌，标志着广药集团大健康板块核心企业全面向科技 型健康企业升级。黄埔区区长冼银崧、广药集团董事长李小军等出席仪式，共同见证这一战略布局落 地。 王老吉总部进驻生物岛 创立于1965年的农心集团，凭借辛拉面等明星产品占据韩国市场第一份额，并成功开拓美、日、澳等国 际市场，是韩食文化全球化的象征。此次与农心集团签约，是王老吉进驻生物岛总部后首个落地的国际 化合作项目。 分析指出，此次合作突显王老吉科技、全球化的双轨战略：一方面依托生物岛科研资源提升产品力，另 一方面借势国际巨头打通海外市场，为中国健康饮料参与全球竞争提供新模式。 南都湾财社记者 黄驰波 作为国家级医药健康创新高地，广州国际生物岛已汇聚超500家顶尖科研机构与企业，成为大健康产业 的"黄金赛道"和竞争力试金石。广药集团早在2019年便投资11亿元在此建设研发销售总部，此次王老吉 率先进驻，将通过生物岛的"灯塔效应"，加速科研创新与数智化转型，构建健康产业新质生产力范本。 广药集团董事长李小军强调，此次总部迁移不仅是空间变革，更是以"悬壶济世"的岭南基因撬动产业转 型，未来将从强化科技创新、拓展国际市场等 ...